High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 3, 2011, Pages 653-654

  Hata, Akito ^a   Kaji, Reiko ^a   Fujita, Shiro ^a   Katakami, Nobuyuki ^a  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ADULT; BRAIN DAMAGE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; DISEASE COURSE; DRUG MEGADOSE; DYSARTHRIA; FEMALE; GAIT DISORDER; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

EID: 79951745868     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d899bb     Document Type: Letter

References (4)

1. Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009;4: 1415-1419.
2. Benedetti G, Latini L, Galetta D, et al. Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib. J Thorac Oncol 2009;4:936-937.
3. Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-smallcell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with highdose gefitinib. J Clin Oncol 2006;24:4517-4520. (Pubitemid 46630993)
4. Dhruva N, Socinski MA. Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol 2009;27: e31-e32.